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Immunization of pregnant women is a promising public health strategy to reduce morbidity and mortal-
ity among both the mothers and their infants. Establishing safety and efficacy of vaccines generally uses a
hybrid design between a conventional interventional study and an observational study that requires
enrolling thousands of study participants to detect an unknown number of uncommon events.
Historically, enrollment of pregnant women in clinical research studies encountered many barriers based
on risk aversion, lack of knowledge, and regulatory ambiguity. Conducting research enrolling pregnant
women in low- and middle-income countries can have additional factors to address such as limited avail-
ability of baseline epidemiologic data on disease burden and maternal and neonatal outcomes during and
after pregnancy; challenges in recruiting and retaining pregnant women in research studies, variability in
applying and interpreting assessment methods, and variability in locally acceptable and available infras-
tructure. Some measures to address these challenges include adjustment of study design, tailoring
recruitment, consent process, retention strategies, operational and logistical processes, and the use of
definitions and data collection methods that will align with efforts globally.
 2017 Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creative-
commons.org/licenses/by/4.0/).1. Introduction
Immunization during pregnancy is already established as an
important public health strategy to prevent maternal and neonatal
tetanus and holds great promise to further reduce infection-related
morbidity and mortality for other diseases among pregnant
women and young infants [1,2]. This is particularly true in low-
and middle-income countries (LMICs), where the burden is great-
est for vaccine-preventable diseases and access to basic health ser-
vices may be limited. Pregnant women are at increased risk ofcertain infectious disease related morbidity and mortality [1,2].
Pregnancies complicated by infection are at higher risk of adverse
pregnancy outcomes, including congenital anomalies, spontaneous
abortion and stillbirth, preterm birth and low-birth weight [1,2].
Immunization in pregnancy may provide protection against infec-
tious diseases to the mother, her developing fetus and the newborn
infant. This is achieved by increasing antibody levels in the mother
against particular infections, so that high and protective levels of
antibody are transferred across the placenta to the fetus and are
retained by the infant during the time of maturation of their
immune system. The success of maternal tetanus vaccination
demonstrated the proof of this principle and is part of routine care
in many countries [1,2]. Influenza and pertussis vaccines are being
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pregnancy programs [3]. Examples of candidate vaccines under
development which have a specific indication for use in pregnancy
include Group B streptococcus, respiratory syncytial virus, cytome-
galovirus, hepatitis E and Zika virus.
Despite the potential benefits of immunization in pregnant
women, there is still reluctance to offer or accept vaccines and
drugs by some health professionals as well as by some pregnant
women [4].
A major source of knowledge about the effects of vaccines on
pregnancy outcomes is primarily from observational studies as
pregnant women historically were excluded from clinical research
of vaccines. More recently, however, clinical trials enrolling preg-
nant women for various vaccines have been performed in the US
and worldwide [5]. Reassuring data regarding the safety and toler-
ability of vaccines in pregnancy has been accumulated from these
prospective clinical trials, as well as from retrospective observa-
tional studies and pregnancy registries [5].
Prospective studies on vaccine safety and efficacy differ from
other types of interventional studies because the enrolled popula-
tion is typically broad, does not have a defining illness, the out-
comes are often uncommon but serious events, and efficacy is
usually defined as a biological rather than a clinical response for
the vast majority of study participants. These factors lead to rela-
tively large studies with attendant infrastructure, logistical,
resource, and analytical needs.
Conducting research in low resource settings is associated with
significant challenges and more so when interventional research is
being conducted with pregnant women. Here we consider the chal-
lenges related to study design, regulatory and evaluation of safety
in clinical trials of vaccines in pregnancy.
There are changes seen in the incidence of the disease, recruit-
ment of pregnant women can be challenging with a high dropout
rate, unrelated adverse events are common and timelines and the
effort for obtaining informed consent and recruitment is often sig-
nificantly more than what was originally planned for. Additional
barriers to conducting clinical research of vaccines in pregnancy,
especially in resource limited settings are the absence of baseline
data on disease burden and maternal and neonatal outcomes, vari-
able infrastructure and logistical capacity, regulatory inconsistency
from one region to another, cultural factors, and overall lack of har-
monization and standards for data collection, assessments, and
analysis [6–8]. The investigators, research team and sponsors need
to be aware of these ground realities and be prepared to be flexible
when unpredictable events occur.2. Product considerations - safety of vaccines
The safety of vaccines administered during pregnancy is a key
consideration for pregnant women, healthcare providers, investi-
gators, regulators, ethics committees, vaccine manufacturers, and
communities. There is a need for a globally harmonized approach
to actively monitor the safety of vaccines used in immunization
programs for pregnant women both during the product develop-
ment and implementation phase [4]. Active post-introduction
surveillance of adverse events following vaccination in pregnancy
is required to complement pre-licensure vaccine safety assess-
ments and to promote availability of high quality data particularly
in the sensitive phase immediately post licensure, where safety
concerns are likely to emerge while effectiveness data may only
just be coming available.
However, there are barriers to the evaluation of the safety of
vaccines in pregnancy in LMICs. There is a lack of standard defini-
tions of maternal and neonatal outcomes, standards for measure-
ment of these outcomes and harmonized study methods [9]. Thislack of harmonization is a challenge for the conduct of clinical
research and observational studies, generalizability of safety data
and strengthening pharmacovigilance programs in LMICs for
immunization in pregnancy and merging of large safety data sets.
Large multi-location data sets could optimize the evaluation of
clinically important adverse events associated with pregnancy
(e.g. microcephaly and congenital abnormalities, stillbirth, preterm
birth, neonatal infections, abortions, fetal growth restriction, fetal
distress etc.) [4,9,10].
Safety assessment of vaccines and drugs utilized in pregnancy
require real-time assessment of risk vs. benefit. Baseline outcome
rates are a useful part of such an assessment. There is little pro-
gress in determining baseline rates in LMIC settings of maternal
and neonatal outcomes [4,9–11].3. Study specific considerations for immunization in pregnancy
in LMICs
3.1. General study design considerations
Studies in LMICs need to address a series of typical methodolog-
ical challenges [12]. For example, baseline incidence rates of preg-
nancy and neonatal outcomes collected through previous studies
or public records inform a series of sample size calculation data.
Unfortunately reliable incidence rates of common disease condi-
tions in LMICs are scarce. Public records are often unreliable and
inconsistent and are gathered by different agencies at different
time points or concurrently, sometimes using different methodolo-
gies. It is highly advantageous to determine or validate these back-
ground rates in the populations being studied prior to the conduct
of the clinical research in that population. Further complicating the
scenario is lack of use of standardized case definitions to distin-
guish conditions like stillbirths frommiscarriages and lack of accu-
rate assessment of gestation age [9,12,13].
3.2. Evaluating potential risks and benefits
As a fetus or infant cannot consent to participation in research, a
critical issue is how much risk is acceptable to impose upon the
fetus or the infant. For research with the potential of direct medical
benefit to the woman or fetus, risk proportionate to the potential
benefit is acceptable. For research that does not involve the pro-
spect of direct medical benefit, risk to the fetus must be no more
than minimal. However, the definitions of minimal risk in the con-
text of pregnancy are unclear [7,12,14].
There is a need to determine adequate methods for estimating
incidence rates, testing hypotheses and determining causal associ-
ations of the outcomes of vaccination in pregnancy in LMIC [13,15–
17] to provide the evidence based reassurance of what are the
actual risks from participation in research. An example is that
major structural or genetic birth defects affect about 3% of all
births in the United States and are associated with 20% of all infant
deaths. Accurate collection and ascertainment of birth defects in
LMICs is lacking [15]. The causal events of most birth defects are
unknown, but some surveys and commentators ascribe participa-
tion in research studies or medical interventions as risk factors
[17].
3.3. Risk adjusted study design
Researchers need to be scientifically strong, responsible and
sensitive to the realities in LMICs while planning research designs
which promote inclusion of pregnant women in research. A key
consideration is maintaining and effectively communicating
maternal and fetal safety. Progressing from healthy adults to
S. Kochhar et al. / Vaccine 35 (2017) 6575–6581 6577‘‘vulnerable populations” is a standard approach in vaccine clinical
research and development (e.g. for infants, children, immuno-
compromised populations). This approach is being applied to
Immunization in Pregnancy research and development and is men-
tioned in the FDA clinical development framework/guidance for
vaccines for pregnant women development [18]. The National
Institute of Allergy and Infectious Diseases used a tiered approach
of analyzing safety and immunogenicity data from a routine H1N1
vaccination program in a general population to generate initial
safety and efficacy information, and subsequently studying the
vaccine in women during the second and third trimester of preg-
nancy This was to minimize the safety concerns and to target the
population most at risk of severe disease from H1N1 infection.
[19–21].
3.4. Inclusion and exclusion criteria
Accurate assessment of gestational age is important to ensure
uniformity in the study population. Gestational age windows are
often specified in the eligibility criteria. It is typically determined
by calculation based on the last menstrual period or measurement
of fundal height, as ultrasound to facilitate more accurate determi-
nation is often unavailable. Pregnant women in LMICs may not
remember their last menstrual period and fundal height assess-
ment is often inaccurate due to the absence of measuring tapes
or busy midwifes and healthcare providers. Visual inspection and
palpation of the abdomen and measurement of fundal height give
a rough idea of the gestational age. This can be estimated by the
use of portable and inexpensive ultrasound machines along with
adequate training of key research teammembers. These staff mem-
bers can subsequently train new staff members and serve as their
mentors. It is helpful to conduct regular quality assurance of the
scans to ensure high quality [12,22].
Recruitment of pregnant women early in pregnancy is often
challenging (as might have to be done for Zika vaccine trials, as
the vaccine, in order to be both timely and effective, will probably
be given either prior to or in early pregnancy). Women will often
not reveal their pregnancy in the first trimester in resource con-
strained settings due to social concerns (due to the fear that harm
might come to the fetus early in pregnancy). This limits the ability
to capture information on fetal development early in pregnancy
[2,7,12].
3.5. Recruitment
In many high income countries (HICs), the bulk of the popula-
tion has access to a universal health care system and study recruit-
ment can utilize the contacts of the general population with the
health care delivery system. The majority of pregnant women
receive some form of prenatal care. In some HIC and LMICs there
is no universal health care system and recruitment involves active
outreach efforts. In many LMICs engagement of community, polit-
ical, or social leaders is a prerequisite to initiating a study. Without
effective partnering with the social hierarchy, a study may never
achieve its goals.
In any research on pregnant women in LMICs, it is often neces-
sary for the study team to gain the trust of the women, her hus-
band/partner, in-laws, extended family and community leaders.
Mistrust can severely affect study recruitment and follow up. Com-
mon misconceptions in LMICs are that the study team collects the
blood samples or conducts autopsies for profit or witchcraft. Any
adverse pregnancy outcome or infant death can be blamed on
study participation. To develop a sense of trust, the site can set
up a Community Advisory Board (CAB) with the help of the Ethics
Committee. The community volunteers are trained on the basics of
clinical research and the phases of clinical trials, research ethicsand the details of the trial. The CAB acts as the liaison between
the research team and the community and represents the interests
of the latter.
It is useful for the study team to partner and work closely with
maternal, neonatal and child health (MNCH), antenatal care (ANC)
providers and local health care providers as they are closely
involved in identifying pregnant women and monitoring their
pregnancy. The midwives and community health workers can be
briefed on the details of the study, inclusion and exclusion criteria,
involvement of the study participants and study outcomes. This is
important for ensuring a strong working relationship with the
community.
In order to reach out to men, in-laws, matriarchs and commu-
nity leaders with influence over women’s participation in clinical
studies that are not easily accessible because they do not attend
antenatal clinics, the research teammembers can conduct commu-
nity meetings around the catchment area which can be organized
through community leaders or in partnership with local non-
governmental organizations (NGOs) working in that particular
field of health and locality/state. This could also include less con-
ventional methods to convey information about research, such as
performances by local street theatre groups. The theatre groups
and meetings can target common misconceptions about clinical
trials and participation of the pregnant women in the research,
while the research team can answer questions about the clinical
research.
Pregnant women in LMICs often will not want to disclose their
pregnancy in the first trimester due to social reasons. For clinical
trials or research studies which include enrolling pregnant women
early in pregnancy, it is useful to emphasize and provide benefits to
early enrolment in antenatal care. This could include covering the
cost of antenatal care, utilizing urine pregnancy tests to test for
pregnancy (which are often not available in public hospitals) for
women who are keen on being screened for study participation if
pregnancy is not clear from physical examination, providing
women in the reproductive age group with hemoglobin testing
and treatment for anemia and providing folic acid and calcium
supplementation if required. Other measures to enable the preg-
nant women to participate in the research include ensuring that
there is support for oversight of small children the pregnant
women might bring with them to the centers for screening or
study visits and providing reimbursement for transportation for
participants enrolling in the research. An ultrasound image of the
fetus that the pregnant women can carry back to share with the
family is often appreciated.
Researchers from local institutions and from abroad often
develop close relationships with the community leaders and public
health workers in the geographical area that they are working in.
They can help to advocate for improvement of public health facil-
ities and local health centers serving the community with Public
Health officials in the country and Donor groups. This is to ensure
that the communities that have volunteered to help with research
get access to the standard of care in the country on a sustainable
basis [6,8,12,17,20,23].
3.6. Informed consent
Researchers are obliged to disclose all research related risks to
the woman and her fetus to obtain consent for participation in clin-
ical research. Disclosure should include risks that are likely to
affect the pregnant women’s decision to participate in the research
[9,12]. Ensuring comprehension of risks is challenging especially
while dealing with women who might have low literacy levels or
be illiterate in LMICs.
Individual autonomy is complex in settings where family and
community have a strong influence on individual choices.
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other than the mother in some low resource settings. Even though
the United States Code of Federal Regulations Title 45 Part 46
clearly states that for studies in which the risk to the fetus is not
greater than minimal, consent of just the pregnant woman is suffi-
cient, in reality, in LMICs, husbands/partners and influential family
members, including in-laws and paternal matriarchs, and commu-
nity leaders are often the key influencers of the pregnant woman’s
decision [12,13,20,24,25]. In LMICs with a high preference for male
offsprings and the prevalence of female infanticide, there might be
a lesser preference for the pregnant women to participate in the
clinical research if it is a male fetus [26].
If desired by the pregnant women, the research team needs to
explain the benefits and risks of her participation in the clinical
trial or study to the family members or other family or community
leaders prior to enrolment. Withdrawal of consent might be seen in
LMICs due to the input of family members. This needs to be kept in
mind while planning the timelines for enrollment and the attrition
rates of the clinical trial or study. Insisting upon identifying, con-
sulting and obtaining additional assent from key decision makers
apart from the consent from the pregnant women prior to enrol-
ment would be an easier option for the research team, but this
would effectively disempower the woman from making decisions
[11,12,20].
More than one third of young women in LMICs are married
before reaching the age of 18 years [27]. Researchers need to con-
sider the implications for consenting adolescent pregnant women
for clinical research. In some countries, women less than 18 years
of age can provide assent to enroll in a study while pregnant while
consent for her participation would have to come from her parent
or legal guardian. But the same women can give consent for her
newborn after delivery [11,12,20].
In LMICs where prenatal medical services are lacking or are
poorly accessed, a potential participant’s first contact with the
research team might be during or prior to labor. There is consider-
able debate on whether pregnant women can provide full consent
during the rigors of labor and delivery. The fact that a pregnant
woman is in labor should not preclude her from providing
informed consent to participate in research. This is because,
women in labor may be able to undergo the appropriate informed
consent process for research like individuals with conditions that
may be painful, life-threatening or emergency situations (e.g.
appendicitis, myocardial infarction) [12,20,21]. Whenever possible,
informed consent should be obtained prior to the onset of labor.
The research team needs to keep culture-specific considerations
in mind, especially for consent for research that involves disclosure
of pregnancy in the first trimester. Further, disclosure of the sex of
the fetus may have consequences of ethical importance especially
in countries with a high rate of female infanticide. Placental sam-
pling, large blood draws from the pregnant women or the neonate
and studies of stillbirth or autopsy are other potentially sensitive
issues [12–15,20].
3.7. Research data collection
Deliveries in LMICs are often not conducted in the health facil-
ities identified by the research team. Capturing data from the
maternity wards is challenging as there is often a single midwife,
or healthcare provider responsible for multiple women in labor.
Women are discharged home quickly with limited assessment of
the women or infant. It is challenging to obtain accurate measure-
ments of birth weight, head circumference, height or temperature
of the neonate.
It is difficult to link the mother and infant records as they often
have different identifying codes in health care records. In the
unfortunate event of a stillbirth or sudden infant death syndrome(SIDS), the women and extended family will often be opposed to
an autopsy being conducted [2,12,28].
For these reasons, detailed logistical planning and intensive
training and quality assurance and quality control measures may
be needed to obtain the data consistency and integrity needed
for regulatory submissions. The return on investment in quality
assurance, quality control and appropriate training cannot be
overemphasized.
3.8. Standard of care considerations
In resource constrained settings, there is often disparity
between the standard of preventive and curative treatment poli-
cies in the country and the access that most women have to those
treatments, which are not commonly available in busy public
health centers.
In LMICs where health services are delivered by community
health workers, traditional birth attendants and midwives, public
health intervention research on maternal and child health often
takes place in homes and not clinics. In these settings, researchers
may need to pay special attention to the need for capacity building
to meet standards of care in the country and ethical obligations to
provide care during the study [12,19,20].
Investigators are obligated to provide clinical trial participants
with the standard of care to which they are entitled. Active detec-
tion and treatment of conditions like anemia, hypertension, malnu-
trition, and infectious diseases will improve the neonatal and
infant outcomes in the study population and might have an impact
of decreasing the background rate of key outcome measures in that
particular population [12,19,20].
3.9. Follow-up
Research often measures immediate maternal and fetal out-
comes; however, long term studies of child development and
women’s health may be needed to detect risks to growth and cog-
nitive development in the fetus and adverse events in the pregnant
women. This is not necessary for all research but needs to be scien-
tifically determined based on the properties of the vaccine, drug or
adjuvant being tested [12,19,20]. It is also important to determine
what would be a practical and implementable follow up duration
in LMICs, where transportation and access to health facilities is
often challenging for the women and infant.
Pregnant women participating in clinical research are often
screened extensively for disease conditions which are considerably
more than the standard antenatal screening offered in LMICs. In a
clinical research or intervention study, the pregnant women are
often asked to attend more antenatal visits than the minimum
number of four antenatal care visits recommended by the World
Health Organization. There is a risk of reduced adherence to follow
up visit schedules over the course of the study [6,12,29].
In LMICs, there is a tradition of women going back to their
maternal homes to deliver their infants at health facilities close
by. This is because the maternal family typically provides care
for the pregnant women and the newborn. In clinical research, only
those women are included who agree to deliver at the designated
health center, but the delivery plans often change over the course
of the pregnancy or they return to the maternal home once the
infants is born [12,29].
In case of adverse events experienced during the course of preg-
nancy, which might be completely unrelated to the study interven-
tion, there is often concern and fear in the pregnant women and
pressure from the extended family. This might lead her to with-
drawing from the study participation [6,12,24]. Pregnant women
receive the standard of care prevalent in the country for infectious
diseases and non-communicable conditions that might alter
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effectiveness of the vaccine in real life settings and increases the
importance of prospective and structured pharmacovigilance stud-
ies post introduction of the vaccine [2,12,30].
4. System considerations
4.1. Current Status of International regulatory guidance
Analysis of available guidelines from regulatory agencies and
others including the Food and Drug Administration (FDA), Euro-
pean Medicines Agency (EMA) and International Conference on
Harmonization of Technical Requirements for Registration of Phar-
maceuticals for Human Use (ICH) highlighted a lack of harmoniza-
tion and expectations for safety monitoring of immunization in
pregnancy [31]. National Regulatory Authorities in LMICs often
refer to the international guidelines for reference. The EMA has
outlined specific requirements for evaluating vaccines in pregnant
women, including: criteria to select medicinal products, including
vaccines, for which active surveillance in pregnancy is necessary;
guidance on how to monitor accidental or intended exposure to
medicinal products during pregnancy; specific requirements for
reporting and presenting data on adverse outcomes of exposure
during pregnancy; risk assessment of medicinal products; and
summary of product characteristics [31,32].
In the FDA and ICH guidelines, general guidance was available
and specific requirements are now emerging with the inclusion
of available data on maternal immunization in the product labeling
[31,33]. In the U.S., many vaccines are approved for use in adults
and most are not contraindicated for use in pregnant women. No
vaccine has approved labeling information for a specific indication
for use during pregnancy. Currently recommended vaccines (e.g.
Tetanus, Diphtheria and acellular Pertussis (Tdap), and inactivated
influenza) by the ACIP (Advisory Committee on Immunization
Practice) are not contraindicated for use during pregnancy and
can be used in pregnant women [31,33].
The FDA recently issued the Pregnancy and Lactation Labeling
Rule (PLLR). This rule will enable the inclusion of a narrative sum-
mary of clinically relevant information on the risks of using a pro-
duct during pregnancy in vaccine and drug labels. This may help
towards communicating information on risks and benefits for
pregnant and lactating women and for males and females of repro-
ductive potential. The new rule allows for incorporating informa-
tion about risk and benefits from a variety of sources, including
clinical trials, pregnancy registries, epidemiologic studies and case
series reporting a rare event. The rule requires evaluation of avail-
able information about the product’s use in pregnancy and needs
to be updated when new information becomes available
[7,31,34,35]. Using standardized case definitions for maternal and
neonatal events will enable pooling of data from clinical and obser-
vational studies for the labels.
Having clarity regarding vaccine and drug labeling related to
pregnancy will help reduce variability in vaccine labels and ensure
that health care providers, and women themselves, have a higher
level of confidence in vaccines to be administered in pregnancy
[36,37]. Well-defined international regulatory guidance could pro-
vide a roadmap for regulatory guidance for immunization in preg-
nancy in LMICs.
4.2. The need for harmonized terminology
The GAIA (Global Alignment of Immunization safety Assessment
in pregnancy) project, funded by the Bill and Melinda Gates Foun-
dation, was set up in response to the call of the World Health Orga-
nization for a globally harmonized approach to activelymonitor the
safety of immunization in pregnancy programswith a specific focuson LMICs needs and requirements. In the GAIA project, experts from
13 organizations (the Brighton Collaboration Foundation (BCF), US
National Institute of Health, World Health Organization, Global
Healthcare Consulting, University of Washington, Baylor College
of Medicine, Monash Institute of Medical Research, St. George’s,
University of London, Erasmus University Medical Center, Cincin-
nati Children’s Hospital, Public Health Agency Canada, Synapse
Research Management Partners and International Alliance for Bio-
logical Standardization) collaborated with over 200 volunteers in
over 25 working groups to respond to this need [9].
During the GAIA project, a global functional network of experts
was assembled [9]. Based on a landscape analysis of available stan-
dards and guidance documents, GAIA partners developed a core set
of 21 globally standardized case definitions of selected key obstetric
and neonatal terms for the assessment of safety of vaccines in preg-
nancy. The team constructed a glossary of enabling terms critical to
these obstetric and neonatal case definitions (e.g. an algorithm for
determination of gestational age) to support stakeholders using
the definitions. In addition, the team developed other resources
such as a searchable database of terms, concept definitions and
ontology of over 3000 terms related to key events for monitoring
immunization in pregnancy [38] and a preliminary map of disease
codes across coding terminologies, including MedDRA (Medical
Dictionary for Regulatory Activities) and ICD (International Classifi-
cation of Diseases) and an online tool for automated case classifica-
tion (single case or batch cases classification) of events according to
the standardized case definitions. The GAIA consortium published
two guideline documents for the collection, analysis and presenta-
tion of safety data in clinical trials of vaccines in pregnantwomen to
provide guidance on the prioritization of the data to be collected in
such studies, and to assist in their applicability in various settings,
including LMICs. These guidelines may also assist in the safety
surveillance of vaccines already recommended for pregnant
women. Guidance on the prioritization of data collection will help
to promote collection of a minimal set of high priority parameters
in various settings, including LMICs [9,31,39,40].
The GAIA outputs are developed based on a standard consensus
process including global consultation of professionals from key
regulatory organizations, public health institutes, investigators,
vaccine manufacturers and academia to ensure their applicability,
usefulness and acceptability especially in LMICs. The WHO Global
Advisory Committee on Vaccine Safety (GACVS) provided a highly
supportive assessment of the key GAIA guidance document and
considered them to be timely and useful. The GAIA outputs are
being increasingly utilized in the field of immunization in preg-
nancy and maternal and child health by key stakeholders such as
clinical trialists, investigators, regulators, and industry.
The use of these definitions, guidelines and tools can be useful in
immunization in pregnancy pre-and post-licensure safety and
pharmacovigilance surveillance systems and help support
enhanced surveillance and collection of safety data that can be con-
solidated and compared across sites, countries, and programs
worldwide. A standardized approach to safety data collection and
reporting is likely to improve the acceptability and implementation
of immunizations in pregnancy and subsequently help reduce ill-
ness and death among pregnant women and young infants globally.5. Conclusion
Conducting immunization in pregnancy research in LMICs is
challenging. This includes the absence of baseline data on maternal
and neonatal outcomes that are commonly seen in pregnancies, lack
of harmonization of the safety data collected, unpredictable changes
in disease epidemiology and cultural beliefs and challenges of
recruiting and retainingpregnantwomen in research.Measures that
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theMNCH and ANC providers in LMICs, community and local health
care system, maintaining flexibility in the study design, learning
from the best practices of conducting research in low resource set-
tings and adapting the lessons to the ground realities in that partic-
ular setting and incentivizing study participation by simple
measures that are easily implementable. Lessons can be learnt from
research inHIC that places emphasis on understanding the effects of
vaccines, drugs and therapies on pregnant women, and ways to
safely include such categories of individuals as subjects in clinical
trials. This research might increase due to provisions for the cover-
age of pregnant women and their product of gestation in the 21st
Century Cures Act in the USA. Reduced liability concerns of vaccine
manufacturers in the US due to the act might also increase research
on pregnant women [41,42]. Due to the complexity of issues
involved, a multidisciplinary collaborative approach is helpful, con-
sisting of investigators, ethicists, clinicians, regulators, Institutional
Review Boards/ethics committee members, community members,
policy makers and pregnant women themselves serving as advo-
cates for their health interests. These measures may help promote
research in low resource settings [2,12,17,20,40,43].
Study Design, Regulatory and Safety Considerations to
conducting immunization in pregnancy clinical research
in LMICs
– Limited availability of baseline epidemiologic data on dis-
ease burden and maternal and neonatal outcomes com-
monly seen in pregnancy
– Lack of harmonization and standards for data collection,
assessments, and analysis
– Cultural beliefs and challenges in recruiting and retaining
pregnant women in research studies
– Challenge of obtaining informed consent
– Variable infrastructure and logistical capacity
Measures to address challenges
– Use of maternal and neonatal outcome definitions and data
collection methods that align with global efforts
– Adequate regulatory guidance to address the issues
– Tailoring the recruitment, consent process and retention
strategies
– Partnering closely with the MNCH, ANC providers, commu-
nity and local health care system
– Maintaining flexibility in the study design
– Learning from the best practices of conducting research in
low resource settings, particularly with regard to logistics,
quality assurance, and training
– Multidisciplinary collaborative approach with investiga-
tors, ethicists, clinicians, regulators, Institutional Review
Boards/ethics committee members, community members,
policy makers and pregnant womenAcknowledgements
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